Evidence map›Paper›PMID 38060175›Full record

ArticleAmerican journal of clinical dermatology2024

Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.

Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Shigetoshi Sano, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Masafumi Yaguchi, Natsuka Uehara and 5 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Tadashi TeruiNihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi, Tokyo, 173-8610, Japan. terui.tadashi@nihon-u.ac.jp.ORCID http://orcid.org/0000-0002-0275-4311
Yukari OkuboTokyo Medical University, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9526-1259
Satomi KobayashiSeibo International Catholic Hospital, Tokyo, Japan.
Shigetoshi SanoKochi Medical School, Kochi University, Kochi, Japan.
Akimichi MoritaNagoya City University, Nagoya, Japan.ORCID http://orcid.org/0000-0001-8372-3754
Shinichi ImafukuFukuoka University, Fukuoka, Japan.
Yayoi TadaTeikyo University, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3743-135X
Masatoshi AbeSapporo Skin Clinic, Sapporo, Japan.
Masafumi YaguchiAmgen K.K., Tokyo, Japan.
Natsuka UeharaAmgen K.K., Tokyo, Japan.
Takahiro HandaAmgen K.K., Tokyo, Japan.
Masayuki TanakaAmgen K.K., Tokyo, Japan.
Wendy ZhangAmgen Inc., Thousand Oaks, CA, USA.
Maria ParisAmgen Inc., Thousand Oaks, CA, USA.
Masamoto MurakamiEhime University Graduate School of Medicine, Ehime, Japan.
Amgen (United States) · USEhime University · JPFukuoka University · JPKōchi University · JPNagoya City University · JPNihon University · JPSapporo Science Center · JPTeikyo University Hospital · JPTokyo Medical University · JPYokohama City Seibu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38060175
PMCPMC10796414
OpenAlexW4389451941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.